Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 10/20 | 0.56 |
| ▸ | TYR | P14679 | 1/20 | 0.52 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | UBE2M | P61081 | 1/20 | 0.42 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6804847 | 1.00 | OPRM1 (0.56) | OPRM1TYRTMEM97SLC6A2SLC6A4 | |
| SCHEMBL7245773 | 0.89 | TYR (0.54) | OPRM1TYRUBE2MDCUN1D1 | |
| SCHEMBL7245757 | 0.89 | TYR (0.54) | OPRM1TYRUBE2MDCUN1D1 | |
| SCHEMBL6810113 | 0.86 | TYR (0.47) | TYRUBE2MDCUN1D1 | |
| SCHEMBL6810116 | 0.86 | TYR (0.47) | TYRUBE2MDCUN1D1 | |
| SCHEMBL5619802 | 0.74 | TYR (0.47) | OPRM1TYR | |
| SCHEMBL5619797 | 0.74 | TYR (0.47) | OPRM1TYR | |
| SCHEMBL4799335 | 0.71 | AGER (0.44) | OPRM1UBE2MDCUN1D1 | |
| SCHEMBL4799331 | 0.71 | AGER (0.44) | OPRM1UBE2MDCUN1D1 | |
| SCHEMBL6799615 | 0.71 | TYR (0.46) | TYR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030190298-A1 | Resorcinol derivatives | BRADLEY STUART E (GB) | 2003-10-09 | — | — | US | claimed |
| US-6541473-B2 | Use as skin lightening agents; 4-(1,4-Dioxaspiro(4.5)dec-8-yl)-1,3-benzenediol for example | WARNER LAMBERT COMPANY | 2003-04-01 | — | — | US | claimed |
| US-20020137961-A1 | Resorcinol derivatives | PFIZER INC. | 2002-09-26 | — | — | US | claimed |
| US-6797731-B2 | USE AS SKIN LIGHTENING AGENTS | PFIZER INC. | 2004-09-28 | — | — | US | disclosed |
| US-20030190298-A1 | Resorcinol derivatives | BRADLEY STUART E (GB) | 2003-10-09 | — | — | US | disclosed |
| US-6541473-B2 | Use as skin lightening agents; 4-(1,4-Dioxaspiro(4.5)dec-8-yl)-1,3-benzenediol for example | WARNER LAMBERT COMPANY | 2003-04-01 | — | — | US | disclosed |
| US-20020137961-A1 | Resorcinol derivatives | PFIZER INC. | 2002-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030190298-A1 | Resorcinol derivatives | LRAT, NQO1, ALDH1A2 | OPRM1 4241/4885TYR 8/4885TMEM97 2705/4885 |
| US-20020137961-A1 | Resorcinol derivatives | LRAT, NQO1, ALDH1A2 | OPRM1 4241/4885TYR 8/4885TMEM97 2705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.